CULVER CITY, Calif.--(BUSINESS WIRE)--Sep. 10, 2016--
NantKwest, Inc (NASDAQ:NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the unique
power of our immune system using natural killer (NK) cells to treat
cancer, infectious diseases and inflammatory diseases, today announced
that the company will be presenting at two investment conferences in
September: The Rodman & Renshaw 2016 Global Healthcare Conference and
the Bank of America Global Healthcare Conference.
Rodman & Renshaw 18th Annual Global
Investment Conference, September, 11-13, 2016, NYC, NY
NantKwest will be presenting and hosting one-on-one meetings at the
Rodman & Renshaw 18th Annual Global Investment Conference
in New York on Monday, September 12, 2016 at the New York Palace Hotel.
Bank of America Global Healthcare Conference, September 14-17, 2016,
NantKwest will be presenting and hosting one-on-one meetings at the Bank
of America Global Healthcare Conference in London on Wednesday,
September 14, 2016 at the Bank of America Merrill Lynch Financial Centre.
About NantKwest Inc.
NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage
immunotherapy company focused on harnessing the unique power of our
immune system using natural killer (NK) cells to treat cancer,
infectious diseases and inflammatory diseases. NK cells are the body’s
first line of defense due to the innate ability of NK cells to rapidly
identify and destroy cells under stress, such as cancer or
NantKwest’s unique NK cell-based platform, with the capacity to grow
active killer cells as a biological cancer therapy, has been designed to
induce cell death against cancer or infected cells by three different
modes of action: (1) Direct killing using activated NK cells (aNK) that
release toxic granules directly into the cell through cell to cell
contact, (2) Antibody-mediated killing using haNKs, which are NK cells
engineered to incorporate a high affinity receptor that binds to an
administered antibody, enhancing the cancer cell killing effect of that
antibody, and (3) Targeted activated killing using taNKs, which are NK
cells engineered to incorporate chimeric antigen receptors (CARs) to
target tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of T cell
therapies including the reduction of risk of serious "cytokine storms"
reported after T cell therapy. As an “off-the-shelf” therapy,
NantKwest's NK cells do not rely on a patient’s own often compromised
immune system. In Phase 1 clinical trials in patients with late stage
cancer, NantKwest's NK cells have been successfully administered as an
outpatient infusion therapy without any reported severe side effects,
even at doses of 10 billion cells.
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, we believe NantKwest is
uniquely positioned to be the premier immunotherapy company and
transform medicine by delivering living drugs in a bag and bringing
novel NK cell-based therapies to routine clinical care. For more
information, please visit http://www.nantkwest.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160910005027/en/
Source: NantKwest Inc.
Jen Hodson, 562-397-3639